JADE BIOSCIENCES INC (JBIO) — insider trading
Health Care · NASDAQ
JADE BIOSCIENCES INC (JBIO) has 16 reported SEC Form 4 insider transactions in our data (latest 2026-06-25).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Eisner Mark | Director | Grant / award / vesting (derivative) | 47,675 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest IV L.P.; Kiselak Tomas; Harwin Peter Evan | Director, 10% owner | Grant / award / vesting (derivative) | 34,843 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Lavelle Erin | Director | Grant / award / vesting (derivative) | 34,843 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Klein Lawrence Otto | Director | Grant / award / vesting (derivative) | 34,843 | $0.00 | $0 | Form 4 |
| 2026-06-09 | DOBMEIER ERIC | Director | Grant / award / vesting (derivative) | 34,843 | $0.00 | $0 | Form 4 |
| 2026-06-09 | CAIN CHRISTOPHER W. | Director | Grant / award / vesting (derivative) | 34,843 | $0.00 | $0 | Form 4 |
| 2026-02-12 | King Andrew James | Officer (See Remarks) | Grant / award / vesting (derivative) | 247,500 | $0.00 | $0 | Form 4 |
| 2026-02-12 | King Andrew James | Officer (See Remarks) | Grant / award / vesting | 41,250 | $0.00 | $0 | Form 4 |
| 2026-02-12 | Frohlich Tom | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 472,500 | $0.00 | $0 | Form 4 |
| 2026-02-12 | Frohlich Tom | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 78,750 | $0.00 | $0 | Form 4 |
| 2026-02-12 | Balta Elizabeth | Officer (See Remarks) | Grant / award / vesting (derivative) | 168,750 | $0.00 | $0 | Form 4 |
| 2026-02-12 | Balta Elizabeth | Officer (See Remarks) | Grant / award / vesting | 28,125 | $0.00 | $0 | Form 4 |
| 2026-02-12 | Dahms Bradford D. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 226,875 | $0.00 | $0 | Form 4 |
| 2026-02-12 | Dahms Bradford D. | Officer (Chief Financial Officer) | Grant / award / vesting | 37,813 | $0.00 | $0 | Form 4 |
| 2025-10-06 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest IV L.P.; Kiselak Tomas; Harwin Peter Evan | Director, 10% owner | Grant / award / vesting (derivative) | 855,047 | $9.14 | $7.82M | Form 4 |
| 2025-10-06 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest IV L.P.; Kiselak Tomas; Harwin Peter Evan | Director, 10% owner | Grant / award / vesting | 1,333,126 | $9.14 | $12.18M | Form 4 |
Ask the chat about JBIO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: JADE BIOSCIENCES INC (JBIO).
Last updated 2026-06-25 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.